Biomea Fusion is expected to report zero revenue and a consensus loss of $0.18 per share for Q3 2026, while its current price of $0.58 trades significantly below the $7.50 average analyst price target.
Investors are primarily focused on the clinical development progress and weight-loss efficacy data for BMF-650, the company’s oral GLP-1 receptor agonist candidate. The company recently reported Phase 1 topline results for BMF-650 showing a 6.1% weight reduction, though the update triggered significant stock volatility. Management is expected to provide further clarity on the Phase 2 COVALENT trials for icovamenib and verify its cash runway, which is currently projected to sustain operations into mid-2027.